Danske Bank A S raised its position in Medline (NASDAQ:MDLN – Free Report) by 25.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 122,100 shares of the company’s stock after purchasing an additional 24,700 shares during the quarter. Danske Bank A S’s holdings in Medline were worth $4,237,000 as of its most recent SEC filing.
A number of other hedge funds have also recently made changes to their positions in MDLN. Mawer Investment Management Ltd. lifted its stake in Medline by 115.1% during the 3rd quarter. Mawer Investment Management Ltd. now owns 1,808,153 shares of the company’s stock worth $62,743,000 after acquiring an additional 967,587 shares in the last quarter. Aberdeen Group plc acquired a new stake in shares of Medline in the third quarter worth $1,270,000. Russell Investments Group Ltd. increased its position in shares of Medline by 4.1% during the third quarter. Russell Investments Group Ltd. now owns 310,908 shares of the company’s stock worth $10,789,000 after acquiring an additional 12,124 shares during the last quarter. Maryland State Retirement & Pension System increased its stake in shares of Medline by 17.4% in the third quarter. Maryland State Retirement & Pension System now owns 27,149 shares of the company’s stock valued at $942,000 after purchasing an additional 4,029 shares during the period. Finally, Jefferies Financial Group Inc. lifted its holdings in shares of Medline by 330.3% in the third quarter. Jefferies Financial Group Inc. now owns 100,000 shares of the company’s stock valued at $3,470,000 after buying an additional 76,761 shares during the period.
Trending Headlines about Medline
These are some of the MDLN headlines that stood out recently:
- Positive Sentiment: The company introduced right-sized Ranpak packaging solutions at distribution centers in Illinois and Texas, an operational efficiency initiative that could reduce packaging waste. Ranpak packaging solutions announcement
- Negative Sentiment: Investors affiliated with Blackstone, Carlyle, Hellman & Friedman, GIC and the Abu Dhabi Investment Authority priced 60 million existing Class A shares at $35.50 each, with an option for underwriters to sell 9 million more. The price is below the recent $39.16 reference level, and the sizable supply may weigh on MDLN; Medline receives no proceeds from the sale. Medline secondary offering pricing
- Negative Sentiment: A law firm announced an investigation into potential securities-law violations related to reported product-quality issues and prior stock declines. This is an investigation, not a finding of wrongdoing, but it adds headline and legal uncertainty. Securities investigation announcement
Insiders Place Their Bets
In related news, major shareholder Private Ltd Gic sold 2,088,987 shares of the company’s stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $35.05, for a total value of $73,218,994.35. Following the sale, the insider directly owned 16,453,806 shares of the company’s stock, valued at $576,705,900.30. This represents a 11.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last quarter, insiders sold 6,348,676 shares of company stock worth $224,525,137. Insiders own 0.81% of the company’s stock.
Medline Trading Up 3.9%
Shares of MDLN stock opened at $39.16 on Thursday. The stock has a market capitalization of $51.51 billion and a PE ratio of 31.14. Medline has a 1-year low of $31.37 and a 1-year high of $50.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 4.04 and a quick ratio of 2.51. The business has a 50-day moving average of $35.49 and a 200 day moving average of $39.29.
Medline (NASDAQ:MDLN – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.12. Medline had a net margin of 1.84% and a return on equity of 8.21%. The business had revenue of $7.86 billion during the quarter. As a group, sell-side analysts anticipate that Medline will post 1.58 earnings per share for the current year.
Wall Street Analysts Forecast Growth
MDLN has been the topic of several research analyst reports. Leerink Partners lifted their price objective on shares of Medline from $43.00 to $46.00 and gave the stock an “outperform” rating in a research report on Thursday, November 5th. Stifel Nicolaus dropped their target price on shares of Medline from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. BTIG Research restated a “buy” rating and set a $55.00 price target on shares of Medline in a report on Thursday, November 5th. Truist Financial dropped their price objective on Medline from $56.00 to $47.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Finally, William Blair reaffirmed an “outperform” rating on shares of Medline in a report on Wednesday, September 23rd. Twenty-three research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $46.08.
View Our Latest Stock Report on Medline
Medline Company Profile
Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations. The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations. Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.
Featured Stories
- Five stocks we like better than Medline
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding MDLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medline (NASDAQ:MDLN – Free Report).
Receive News & Ratings for Medline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medline and related companies with MarketBeat.com's FREE daily email newsletter.
